Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma

被引：39
|
作者：
Allmeroth, Kira [1 ]
Horn, Moritz [2 ]
Kroef, Virginia [1 ]
Miethe, Stephan [1 ]
Mueller, Roman-Ulrich [3 ,4 ,5 ,6 ]
Denzel, Martin S. [1 ,3 ,6 ]
机构：
[1] Max Planck Inst Biol Ageing, Joseph Stelzmann Str 9b, D-50931 Cologne, Germany
[2] Acus Labs GmbH, Max Planck Inst Biol Ageing, Joseph Stelzmann Str 9b, D-50931 Cologne, Germany
[3] Univ Cologne, CECAD Cluster Excellence, Joseph Stelzmann Str 26, D-50931 Cologne, Germany
[4] Univ Cologne, Fac Med, Dept Internal Med 2, Kerpener Str 62, D-50937 Cologne, Germany
[5] Univ Cologne, Univ Hosp Cologne, Kerpener Str 62, D-50937 Cologne, Germany
[6] Univ Cologne, Ctr Mol Med Cologne CMMC, Robert Koch Str 21, D-50931 Cologne, Germany
来源：
LEUKEMIA | 2021年 / 35卷 / 03期
关键词：
20S PROTEASOME;
D O I：
10.1038/s41375-020-0989-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：887 / 892
页数：6
相关论文
共 48 条
  • [21] Acquisition of Mutations in the PSMB5 Gene during Chronic Exposure of Human Acute Lymphoblastic Leukemia CCRF-CEM Cells to the Proteasome Inhibitor Bortezomib.
    Franke, Niels E.
    Oerlemans, Ruud
    van Zantwijk, Ina
    Vojtekova, Katarina
    Kaspers, Gertjan L.
    Jansen, Gerfit
    Cloos, Jacqueline
    BLOOD, 2008, 112 (11) : 914 - 914
  • [22] Response to Repotrectinib After Development of NTRK Resistance Mutations on First- and Second-Generation TRK Inhibitors
    Chen, Monica F.
    Yang, Soo-Ryum
    Shia, Jinru
    Girshman, Jeffrey
    Punn, Sippy
    Wilhelm, Clare
    Kris, Mark G.
    Cocco, Emiliano
    Drilon, Alexander
    Raj, Nitya
    JCO PRECISION ONCOLOGY, 2023, 7
  • [23] The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib
    Robak, Pawel
    Jarych, Dariusz
    Mikulski, Damian
    Drozdz, Izabela
    Weglowska, Edyta
    Kotkowska, Aleksandra
    Misiewicz, Malgorzata
    Smolewski, Piotr
    Stawiski, Konrad
    Fendler, Wojciech
    Szemraj, Janusz
    Robak, Tadeusz
    CANCERS, 2021, 13 (05) : 1 - 17
  • [24] Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma
    Zhou, Yi
    Liu, Xiaoting
    Xue, Junxin
    Liu, Lulu
    Liang, Tao
    Li, Wen
    Yang, Xinying
    Hou, Xuben
    Fang, Hao
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (09) : 4701 - 4715
  • [25] Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma
    Sullivan, Daniel M.
    Kashyap, Trinayan
    Dawson, Jana L.
    Landesman, Yosef
    Grant, Steven
    Shain, Kenneth H.
    Dai, Yun
    Kauffman, Michael
    Shacham, Sharon
    Turner, Joel C.
    BLOOD, 2015, 126 (23)
  • [26] A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma
    A K Mitra
    T Harding
    U K Mukherjee
    J S Jang
    Y Li
    R HongZheng
    J Jen
    P Sonneveld
    S Kumar
    W M Kuehl
    V Rajkumar
    B Van Ness
    Blood Cancer Journal, 2017, 7 : e581 - e581
  • [27] A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma
    Mitra, A. K.
    Harding, T.
    Mukherjee, U. K.
    Jang, J. S.
    Li, Y.
    HongZheng, R.
    Jen, J.
    Sonneveld, P.
    Kumar, S.
    Kuehl, W. M.
    Rajkumar, V.
    Van Ness, B.
    BLOOD CANCER JOURNAL, 2017, 7 : e581 - e581
  • [28] Development of a pharmacodynamic assay for the second-generation proteasome inhibitor MLN9708 in clinical trials of multiple myeloma
    Jie, Yu
    Yang, Yu
    Stringer, Bradley
    Babcock, Trisha
    Bowman, Doug
    Cao, Yueying
    Donelan, Jill
    Fleming, Mark
    Kupperman, Erik
    Lee, Edmund
    Lightcap, Eric
    Zhang, Julie
    Berger, Allison
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [29] Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors
    Tam, Constantine S.
    Balendran, Shalini
    Blombery, Piers
    BLOOD, 2025, 145 (10) : 1005 - 1009
  • [30] Mechanisms of activity and drug resistance with proteasome inhibitors in multiple myeloma: Comparison of bortezomib and the investigational drug MLN9708
    Bianchi, Giada
    Ramakrishnan, Vijay G.
    Kimlinger, Teresa K.
    Haug, Jessica
    Rajkumar, S. Vincent
    Kumar, Shaji
    CANCER RESEARCH, 2012, 72
12345